
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

**Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

**Date of Report: July 24, 2017
Commission File Number: 001-36891**

Collectis S.A.

(Exact Name of registrant as specified in its charter)

8, rue de la Croix Jarry
75013 Paris, France
+33 1 81 69 16 00

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

EXHIBIT INDEX

Exhibit **Title**

99.1 Press release, dated **July 24, 2017**.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CELLECTIS S.A.
(Registrant)

July 24, 2017

By: /s/ André Choulika
André Choulika
Chief Executive Officer

Collectis Granted Patent for CRISPR Use in T-Cells

NEW YORK--(BUSINESS WIRE)--July 24, 2017--Regulatory News:

Collectis (Paris:ALCLS) (NASDAQ:CLLS) (Alternext: ALCLS; Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells. The patent will be issued on August 2, 2017.

This therapeutic-focused patent follows previous intellectual property that Collectis has obtained over the two last decades for major gene editing technologies including meganucleases, TALEN[®], MegaTAL and CRISPR.

“Collectis is a pioneering gene editing company that has always been at the forefront of all gene editing technologies,” said Dr. André Choulika, Collectis Chairman & CEO. “We have been the first to explore the potential of CRISPR in its early days in various applications, including therapeutics and food, and these early findings ultimately led to the grant of this new patent. While Collectis has selected TALEN[®] as the most robust and adaptable technology for human therapeutic use and for the Company’s product pipeline, our team does sometimes use CRISPR-based nucleases for T-cell research, as it is a less-expensive option and convenient for gene discovery purposes. As such, this patent only further reinforces Collectis’ leadership position in the gene editing industry, with more patents coming down the pike for the Company in the near future.”

Convinced of its strong value for future development of engineered CAR T-cells, Collectis will make this patent available for licensing to companies that are willing to use this technology in T-cells.

The inventors of this patent are Dr. André Choulika, Chairman & CEO of Collectis and one of the pioneers in the development of nuclease-based genome editing technologies; Dr. Philippe Duchateau, Collectis Chief Scientific Officer and seasoned gene editing expert and Dr. Laurent Poirot, Collectis Head of Early Discovery and expert of gene functions in immune cells.

Claim 1 of the EP3004337 patent

1) A method of preparing T-cells for immunotherapy comprising the steps of:

- (a) Genetically modifying T-cells by introduction into the cells and/or expression in the cells of at least:
 - a RNA-guided endonuclease; and
 - a specific guide RNA that directs said endonuclease to at least one targeted locus in the T-cell genome, wherein said RNA-guided endonuclease is expressed from transfected mRNA, and said guide RNA is expressed in the cells as a transcript from a DNA vector;
-

(b) expanding the resulting cells in vitro.

About Collectis

Collectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited T-cells (UCART). By capitalizing on its 17 years of expertise in gene editing – built on its flagship TALEN® technology and pioneering electroporation system PulseAgile – Collectis uses the power of the immune system to target and eradicate cancer cells. Using its life-science-focused, pioneering genome engineering technologies, Collectis' goal is to create innovative products in multiple fields and with various target markets. Collectis is listed on the Nasdaq market (ticker: CLLS) and on the NYSE Alternext market (ticker: ALCLS). To find out more about us, visit our website: www.collectis.com

Talking about gene editing? We do it. TALEN® is a registered trademark owned by the Collectis Group.

Disclaimer

This press release and the information contained herein do not constitute an offer to sell or subscribe, or a solicitation of an offer to buy or subscribe, for shares in Collectis in any country. This press release contains forward-looking statements that relate to the Company's objectives based on the current expectations and assumptions of the Company's management only and involve risk and uncertainties that could cause the Company to fail to achieve the objectives expressed by the forward-looking statements above.

CONTACT:

Media:

Collectis

Jennifer Moore, 917-580-1088

VP of Communications

media@collectis.com

or

Caitlin Kasunich, 212-896-1241

KCSA Strategic Communications

ckasunich@kcsa.com

or

IR:

Simon Harnest, 646-385-9008

VP of Corporate Strategy and Finance

simon.harnest@collectis.com